Received Jul 2, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | AZ2A3 | — |
she received what should have been her Third dose of Twinrix but it was her Second; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 57-year-old female patient who received HAB (Twinrix) suspension for injection in pre-filled syringe (batch number AZ2A3 with expiry date 05-FEB-2028 and batch number KD27Z with expiry date 08-SEP-2028) for prophylaxis. Previously administered products included Twinrix (first dose was received on 02-DEC-2025 with batch number AZ2A3). On 25-JUN-2026, the patient received the 2nd dose of Twinrix. On 25-JUN-2026, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: she received what should have been her Third dose of Twinrix but it was her Second). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-JUN-2026 The pharmacist reported about a patient who was doing some pretravel vaccinations. She was supposed to be receiving a series of the Twinrix vaccines. Though when it was time for her second dose, she received it in another location, they gave her the Heplisav instead of her second dose of the Twinrix. Then, on the day of reporting she received what should have been her third dose of Twinrix but it was her second. So, the pharmacist enquired if they need to do any catch-up dosing on the Hepatitis A portion or just continuing with the third dose of Twinrix to complete the series.